Skip to main content
NCBI home page
Current Therapeutic Research, Clinical and Experimental logoLink to Current Therapeutic Research, Clinical and Experimental
. 2006 May;67(3):174–192. doi: 10.1016/j.curtheres.2006.06.004

Effects of combination treatment with policosanol and omega-3 fatty acids on platelet aggregation: A randomized, double-blind clinical study

Gladys Castaño 1, Maria L Arruzazabala 2, Lilia Fernández 2, Rosa Mas 2,**, Daisy Carbajal 2, Vivian Molina 2, José Illnait 1, Sarahí Mendoza 1, Rafael Gámez 1, Melbis Mesa 1, Julio Fernández 2
PMCID: PMC3965964  PMID: 24678094

Abstract

Background:

Policosanol is a mixture of long-chain primary aliphatic alcoholspurified from sugar cane wax that has cholesterol lowering and antiplatelet effects. Omega-3 fatty acids (FA) have triglyceride lowering and antiplatelet effects. Combination treatment with policosanol and omega-3 FA (Ω23FA) has been associated with significant inhibition of platelet aggregation in rabbits compared with either drug alone.

Objective:

The aim of this study was to investigate the effects of combination treatment with Ω3FA (1 g/d) and policosanol (Ω3FA+Poli) compared with Ω3FA (1 g/d) plus placebo (Ω3FA+Pla) on platelet aggregation in human patients with hypercholesterolemia.

Methods:

This randomized, double-blind, clinical study at the Surgical Medical Research Center (Havana City, Cuba) recruited outpatients from lipid clinics, with some atherosclerotic risk factors. Outpatients of both sexes aged 20 to 75 years with serum total cholesterol (TC) levels ≥5 and <6 mmol/L were eligible to enroll. They were included in the study at the end of a 4-week diet stabilization period if their platelet aggregation to arachidonic acid (AA) was ≥50% and serum TC level remained ≥5 mmol/L. Patients were then evenly randomized to receive Ω3FA (1 g/d) + placebo or Ω3FA (1 g/d) + policosanol (10 mg/d) to be taken PO with the evening meal for 21 days. Treatment was assigned according to a randomization code using balanced blocks and a 1:1 allocation ratio. Inhibition of platelet aggregation to AA was the primary efficacy variable, while effects on platelet aggregation to collagen and epinephrine and on lipid profile were secondary variables. Drug compliance and adverse events (AEs) were monitored. Tolerability was assessed using physical examinations and laboratory test results.

Results:

Sixty-four subjects were initially enrolled. Fifty-four patients (30 women, 24 men; mean [SD] age, 58.4 [12] years, [range, 40–70 years]) met the inclusion criteria and were randomized to treatment; 2 groups of 27. After 21 days, platelet aggregation to AA was significantly inhibited in the 2 groups. Ω3FA+Poli inhibited platelet aggregation to all agonists by ≥20%. Platelet aggregation to AA 1.0 and 1.5 mM was inhibited with combination treatment (39.6% and 33.9%, respectively; both P < 0.001 vs baseline; P < 0.001 and P < 0.01, respectively, vs Ω3FA+Pla) and with Ω3FA+Pla (11.0% and 13.3%; both, P < 0.001). Combination treatment was more effective in inhibiting platelet aggregation to AA 1.0 and 1.5 mM in 28.6% (P < 0.001) and 20.6% (P < 0.01), respectively. Platelet aggregation to collagen 1 μg/mL was significantly inhibited with combination treatment and with Ω3FA+Pla compared with baseline (43.2% and 15.1%, respectively; both, P < 0.001), but the effects of combination treatment were significantly greater (P < 0.01). Platelet aggregation to epinephrine 0.1 mM was inhibited with Ω3FA+Poli and Ω3FA+Pla (34.8% and 20.1%; both, P < 0.001), with similar results for both groups. Bleeding time did not change significantly for either group and Ω3FA+Pla did not significantly change the lipid profile. Combination treatment did significantly reduce levels of low-density lipoprotein cholesterol (LDL-C) (17.4%; P < 0.001 vs baseline, P < 0.05 vs Ω3FA+Pla) and TC (10.1%; P < 0.001 vs baseline, P < 0.05 vs Ω3FA+Pla), increase high-density lipoprotein cholesterol (HDL-C) levels (18.0%; P < 0.001 vs baseline), but did not significantly change triglyceride levels. Three patients (2 from the Ω3FA+Poli group and 1 from the Ω3FA+Pla group) withdrew from the trial, though none were due to AEs. Two patients receiving combination treatment reported mild AEs (headache). All treatments were well tolerated.

Conclusions:

In these patients, policosanol (10 mg/d) administered concomitantly with Ω3FA (1 g/d) enhanced the inhibition of platelet aggregation to AA and collagen, but not to epinephrine, compared with Ω3FA+Pla, without significantly affecting bleeding time. Concomitant treatment was also associated with reduced levels of LDL-C and TC and raised HDL-C levels. All treatments were well tolerated.

Key words: policosanol, omega-3 fatty acids, platelet aggregation, antiplatelet drugs, cholesterol-lowering drugs

Full Text

The Full Text of this article is available as a PDF (1.1 MB).

References

  • 1.Wu K.K. Recent advances in hemostatic risk factors and cardiovascular diseases. Fibrinolysis & Proteolysis. 1997;11(Suppl 1):31–34. [Google Scholar]
  • 2.Murray C.J., Lopez A.D. Alternative projections of mortality and disability by cause 1990–2020. Global Burden of Disease Study. Lancet. 1997;349:1498–1504. doi: 10.1016/S0140-6736(96)07492-2. [DOI] [PubMed] [Google Scholar]
  • 3.The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351–364. doi: 10.1001/jama.1984.03340270029025. [DOI] [PubMed] [Google Scholar]
  • 4.The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–374. [PubMed] [Google Scholar]
  • 5.Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–1389. [PubMed] [Google Scholar]
  • 6.Sacks F.M., Pfeffer M.A., Moye L.A., Cholesterol and Recurrent Events Trial Investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009. doi: 10.1056/NEJM199610033351401. [DOI] [PubMed] [Google Scholar]
  • 7.The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterollevels. N Engl J Med. 1998;339:1349–1357. doi: 10.1056/NEJM199811053391902. [DOI] [PubMed] [Google Scholar]
  • 8.Shepherd J, Cobbe S.M., Ford I., West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307. doi: 10.1056/NEJM199511163332001. [DOI] [PubMed] [Google Scholar]
  • 9.Downs J.R., Clearfield M., Weis S., Air Force/Texas Coronary Atherosclerosis Prevention Study Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622. doi: 10.1001/jama.279.20.1615. [DOI] [PubMed] [Google Scholar]
  • 10.Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet. 2002;360:7–22. [Google Scholar]
  • 11.Shepherd J, Blauw G.J., Murphy M.B., PROSPER Study Group (PROspective Study of Pravastatin in the Elderly at Risk). Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomisedcontrolled trial. Lancet. 2002;360:1623–1630. doi: 10.1016/s0140-6736(02)11600-x. [DOI] [PubMed] [Google Scholar]
  • 12.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA. 2001;285:2486–2497. doi: 10.1001/jama.285.19.2486. [DOI] [PubMed] [Google Scholar]
  • 13.Gotto A.M., Jr, Assmann G, Carmena R. 2nd ed. International Lipid Information Bureau; New York, NY: 2000. The ILIB Lipid Handbook for Clinical Practice: Blood Lipids and Coronary Heart Disease. [Google Scholar]
  • 14.Falk E., Fernandez-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol. 1995;75:3B–11B. doi: 10.1016/0002-9149(95)80003-b. [DOI] [PubMed] [Google Scholar]
  • 15.Schafer A.I. Antiplatelet therapy. Am J Med. 1996;101:199–209. doi: 10.1016/s0002-9343(96)80077-5. [DOI] [PubMed] [Google Scholar]
  • 16.Haller H. Endothelial function. General considerations. Drugs. 1997;53(Suppl 1):1–10. doi: 10.2165/00003495-199700531-00003. [DOI] [PubMed] [Google Scholar]
  • 17.Luscher T.F., Barton M. Biology of the endothelium. Clin Cardiol. 1997;20(Suppl 2):113–1110. [PubMed] [Google Scholar]
  • 18.Shah P.K. Plaque disruption and coronary thrombosis: New insight into pathogenesis and prevention. Clin Cardiol. 1997;20(Suppl 12):1138–1144. [PubMed] [Google Scholar]
  • 19.Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction and stroke by prolongedantiplatelet therapy in various categories of patients. BMJ. 1994;308:81–106. [published correction appears in BMJ. 1994;308:1540] [PMC free article] [PubMed] [Google Scholar]
  • 20.Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J. 1998;19(Suppl A):A12–A19. [PubMed] [Google Scholar]
  • 21.Hassan M., Amonkar M. Aspirin use for primary and secondary prophylaxis of cardiovascular disease. Curr Ther Res Clin Exp. 2001;62:676–690. [Google Scholar]
  • 22.Patrono C., Coller B., Dalen J.E. Platelet-active drugs: The relationships among dose, effectiveness, and side effects. Chest. 2001;119(Suppl 1):39S–63S. doi: 10.1378/chest.119.1_suppl.39s. [DOI] [PubMed] [Google Scholar]
  • 23.Mas R. Policosanol. Drugs of the Future. 2000;25:569–586. [Google Scholar]
  • 24.Ortensi G., Gladstein J., Valli H., Tesone P.A. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res Clin Exp. 1997;58:390–401. [Google Scholar]
  • 25.Mas R, Castano G., Illnait J. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther. 1999;65:439–447. doi: 10.1016/S0009-9236(99)70139-6. [DOI] [PubMed] [Google Scholar]
  • 26.Castano G., Mas R., Arruzazabala M.L. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients. Int J Cl in Pharmacol Res. 1999;19:105–116. [PubMed] [Google Scholar]
  • 27.Castano G., Mas R., Fernandez L. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol. 2000;14:187–195. doi: 10.3109/09513590009167681. [DOI] [PubMed] [Google Scholar]
  • 28.Mas R., Castano G., Fernandez L. Effects of policosanol on lipid profile and cardiac events in older hypercholesterolaemic patients with coronary disease. Clin Drug Invest. 2001;21:485–497. [Google Scholar]
  • 29.Castano G, Mas R., Fernandez L. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging. 2003;20:153–163. doi: 10.2165/00002512-200320020-00006. [DOI] [PubMed] [Google Scholar]
  • 30.Torres O, Agramonte A.J., Illnait J. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care. 1995;18:393–397. doi: 10.2337/diacare.18.3.393. [DOI] [PubMed] [Google Scholar]
  • 31.Crespo N., Illnait J., Mas R. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and noninsulin dependentdiabetes mellitus. Int J Clin Pharmacol Res. 1999;19:117–127. [PubMed] [Google Scholar]
  • 32.Castano G., Fernandez L., Mas R. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2diabetes mellitus. Clin Drug Invest. 2003;23:639–650. doi: 10.2165/00044011-200323100-00003. [DOI] [PubMed] [Google Scholar]
  • 33.Menendez R, Fernandez S.I., Del Rio A. Policosanol inhibits cholesterol biosynthesis and enhances low density lipoprotein processing in cultured human fibroblasts. Biol Res. 1994;27:199–203. [PubMed] [Google Scholar]
  • 34.Menendez R., Arruzazabala M.L., Mas R. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet. Br J Nutr. 1997;77:923–932. doi: 10.1079/bjn19970090. [DOI] [PubMed] [Google Scholar]
  • 35.Menendez R, Amor A.M., Rodeiro I. Policosanol modulates HMG-CoA reductase activity in cultured fibroblasts. Arch Med Res. 2001;32:8–12. doi: 10.1016/s0188-4409(00)00265-4. [DOI] [PubMed] [Google Scholar]
  • 36.Arruzazabala M.L., Valdes S., Mas R. Effect of policosanol successive dose increases on platelet aggregation in healthy volunteers. Pharmacol Res. 1996;34:181–185. doi: 10.1006/phrs.1996.0086. [DOI] [PubMed] [Google Scholar]
  • 37.Arruzazabala M.L., Mas R., Molina V. Effect of policosanol on platelet aggregation in type II hypercholesterolemic patients. Int J Tissue React. 1998;20:119–124. [PubMed] [Google Scholar]
  • 38.Menendez R, Mas R., Amor A.M. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol. 2000;50:255–262. doi: 10.1046/j.1365-2125.2000.00250.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Menendez R., Mas R., Amor A.M. Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to invitro copper-mediated lipid peroxidation: A randomized, double-blind pilot study. Curr Ther Res Clin Exp. 2000;61:609–620. [Google Scholar]
  • 40.Gamez R, Aleman C.L., Mas R. A 6-month study on the toxicity of high doses of policosanol orally administered to Sprague-Dawley rats. J Med Food. 2001;4:57–65. doi: 10.1089/109662001300341707. [DOI] [PubMed] [Google Scholar]
  • 41.Mesa A.R., Mas R., Noa M. Toxicity of policosanol in beagle dogs: One-year study. Toxicol Lett. 1994;73:81–90. doi: 10.1016/0378-4274(94)90098-1. [DOI] [PubMed] [Google Scholar]
  • 42.Rodriguez M.D., Garcia H. Teratogenic and reproductive studies of policosanol in the rat and rabbit. Teratog Carcinog Mutagen. 1994;14:107–113. doi: 10.1002/tcm.1770140302. [DOI] [PubMed] [Google Scholar]
  • 43.Aleman C.L., Mas Ferreiro R., Noa Puig M. Carcinogenicity of policosanol in Sprague Dawley rats: A 24 month study. Teratog Carcinog Mutagen. 1994;14:239–249. doi: 10.1002/tcm.1770140505. [DOI] [PubMed] [Google Scholar]
  • 44.Fernandez L., Mas R., Illnait J., Fernandez J.C. Policosanol: Results of a postmarketing surveillance study of 27,879 patients. Curr Ther Res Clin Exp. 1998;59:717–722. [Google Scholar]
  • 45.Mas R., Rivas P., Izquierdo J.E. Pharmacoepidemiologic study of policosanol. Curr Ther Res Clin Exp. 1999;60:458–467. [Google Scholar]
  • 46.Harris W.S., Park Y., Isley W.L. Cardiovascular disease and long-chain omega-3 fatty acids. Curr Opin Lipidol. 2003;14:9–14. doi: 10.1097/00041433-200302000-00003. [DOI] [PubMed] [Google Scholar]
  • 47.Lee K.W., Lip G.Y. The role of omega-3 fatty acids in the secondary prevention of cardiovascular disease. QJM. 2003;96:465–480. doi: 10.1093/qjmed/hcg092. [DOI] [PubMed] [Google Scholar]
  • 48.Richter W.O. Long-chain omega-3 fatty acids from fish reduce sudden cardiac death in patients with coronary heart disease. Eur J Med Res. 2003;8:332–336. [PubMed] [Google Scholar]
  • 49.Lemaitre R.N., King I.B., Mozaffarian D. n-3 Polyunsaturated fatty acids, fatal ischemic heart disease, and nonfatal myocardial infarction in older adults: The Cardiovascular Health Study. Am J Clin Nutr. 2003;77:319–325. doi: 10.1093/ajcn/77.2.319. [DOI] [PubMed] [Google Scholar]
  • 50.Oh R. Practical applications of fish oil (omega-3 fatty acids) in primary care. J Am Board Fam Pract. 2005;18:28–36. doi: 10.3122/jabfm.18.1.28. [DOI] [PubMed] [Google Scholar]
  • 51.De Caterina R., Madonna R., Zucchi R., La Rovere M.T. Antiarrhythmic effects of omega-3 fatty acids: From epidemiology to bedside. Am Heart J. 2003;146:420–430. doi: 10.1016/S0002-8703(03)00327-2. [published corrections appear in Am Heart J. 2004;147:IN1 and Am Heart J 2004;147:874] [DOI] [PubMed] [Google Scholar]
  • 52.Mori T.A., Beilin L.J. Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction. Curr Opin Lipidol. 2001;12:11–17. doi: 10.1097/00041433-200102000-00003. [DOI] [PubMed] [Google Scholar]
  • 53.Gamez R., Maz R., Arruzazabala M.L. Effects of concurrent therapy with policosanol and omega-3 fatty acids on lipid profile and platelet aggregation of rabbits. Drugs R D. 2005;6:11–19. doi: 10.2165/00126839-200506010-00002. [DOI] [PubMed] [Google Scholar]
  • 54.Castano G, Fernandez L., Mas R. Effects of addition of policosanol to omega-3 fatty acid therapy on the lipid profile of patients with type II hypercholesterolaemia. Drugs R D. 2005;6:207–219. doi: 10.2165/00126839-200506040-00003. [DOI] [PubMed] [Google Scholar]
  • 55.Schectman G., Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197–204. doi: 10.1016/s0002-9343(97)89459-4. [DOI] [PubMed] [Google Scholar]
  • 56.Naranjo C.A., Busto U., Sellers E.M. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245. doi: 10.1038/clpt.1981.154. [DOI] [PubMed] [Google Scholar]
  • 57.Born G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature. 1962;194:927–929. doi: 10.1038/194927b0. [DOI] [PubMed] [Google Scholar]
  • 58.Seigler L., Wu W.T. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate andmagnesium chloride. Clin Chem. 1981;27:838–841. [PubMed] [Google Scholar]
  • 59.Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultra-centrifuge. Clin Chem. 1972;18:499–502. [PubMed] [Google Scholar]
  • 60.Din J.N., Newby D.E., Flapan A.D. Omega 3 fatty acids and cardiovascular disease—fishing for a natural treatment. BMJ. 2004;328:30–35. doi: 10.1136/bmj.328.7430.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Masley S.C. Dietary therapy for preventing and treating coronary artery disease. Am Fam Physician. 1998;57:1299–1306. [PubMed] [Google Scholar]
  • 62.Mori T.A., Beilin L.J., Burke V. Interactions between dietary fat, fish, and fish oils and their effects on platelet function in men at risk of cardiovascular disease. Arterioscler Thromb Vasc Biol. 1997;17:279–286. doi: 10.1161/01.atv.17.2.279. [DOI] [PubMed] [Google Scholar]
  • 63.Agren J.J., Vaisanen S., Hanninen O. Hemostatic factors and platelet aggregation after a fish-enriched diet or fish oil or docosahexaenoic acid supplementation. Prostaglandins Leukot Essent Fatty Acids. 1997;57:419–421. doi: 10.1016/s0952-3278(97)90421-x. [DOI] [PubMed] [Google Scholar]
  • 64.Winther K., Myrup B., Holmer G. Decreased platelet activity without change in fibrinolytic activity after low dosages of fish oil. Angiology. 1993;44:39–44. doi: 10.1177/000331979304400107. [DOI] [PubMed] [Google Scholar]
  • 65.von Schacky C., Fischer S., Weber P.C. Long-term effects of dietary marine omega-3 fatty acids upon plasma and cellular lipids, platelet function, and eicosanoid formation in humans. J Clin Invest. 1985;76:1626–1631. doi: 10.1172/JCI112147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.von Schacky C., Weber P.C. Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans. J Clin Invest. 1985;76:2446–2450. doi: 10.1172/JCI112261. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Arruzazabala M.L., Carbajal D., Molina V. Pharmacological study of the interaction between policosanol and aspirin in experimentation animals. Rev Iberoam Tromb Hemost. 1992;5:17–20. [in Spanish] [Google Scholar]
  • 68.Arruzazabala M.L., Molina V., Carbajal D. Effect of policosanol on cerebral ischemia in Mongolian gerbils: Role of prostacyclin and thromboxane A2. Prostaglandins Leukot Essent Fatty Acids. 1993;49:695–697. doi: 10.1016/0952-3278(93)90080-g. [DOI] [PubMed] [Google Scholar]
  • 69.Carbajal D., Arruzazabala M.L., Valdes S., Mas R. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers. Prostaglandins Leukot Essent Fatty Acids. 1998;58:61–64. doi: 10.1016/s0952-3278(98)90130-2. [DOI] [PubMed] [Google Scholar]

Articles from Current Therapeutic Research, Clinical and Experimental are provided here courtesy of Elsevier

RESOURCES